IKZF1-degrader-2 (Compound 3) is a targeted molecular glue that induces selective degradation of IKZF1, demonstrating potent anticancer efficacy with an advantageous safety profile.

Z-NCTS is a sequence-selective RNA-binding molecule that specifically targets 5’-r(XGG)-3’/5’-r(XGG)-3’ mismatches (where X = U or A), functioning as a molecular glue to stabilize these RNA duplex structures.

CQ627 is a targeted molecular glue that promotes RIOK2 degradation through the ubiquitin-proteasome pathway by bridging interactions between RIOK2 and the E3 ligase RNF126, achieving a DC50 of 410 nM in MOLT4 leukemia cells. This compound demonstrates multi-modal anticancer activity, including: (1) dose-dependent apoptosis induction, (2) G2/M phase cell cycle arrest, and (3) broad-spectrum antiproliferative effects across cancer cell lines. Furthermore, CQ627 shows significant in vivo efficacy in MOLT4 xenograft models, validating its therapeutic potential.

STING Degrader-1 (compound 2) is a covalent molecular glue that simultaneously engages STING and its cognate E3 ligase, inducing targeted protein degradation. The compound exhibits a characteristic hook effect, achieving maximal STING depletion (75%) at 10 μM, while higher concentrations (30 μM) show reduced degradation efficiency (~30%).

GSPT1 degrader-2 (Compound 210) is an orally bioavailable molecular glue that achieves potent, sub-30 nM degradation of GSPT1 (DC50 < 30 nM), demonstrating robust antitumor efficacy in preclinical models.

GSPT1 degrader-1 (compound 9q) is a potent molecular glue that mediates targeted degradation of G1-to-S phase transition protein 1 (GSPT1) through the ubiquitin-proteasome pathway. This compound exhibits dual biological activity by inducing cell cycle arrest at the G0/G1 phase checkpoint and triggering apoptotic signaling cascades.

IKZF3 degrader 1 (compound 19a) is a potent molecular glue that induces targeted IKZF3 degradation (EC50 = 12 nM) by facilitating its recruitment to the cereblon (CRBN) E3 ubiquitin ligase complex. This enforced protein-protein interaction triggers subsequent ubiquitination and proteasomal elimination of IKZF3.

AR Degrader-1 (Compound ML 2-9) is a monovalent molecular glue that selectively targets the androgen receptor (AR) for degradation via recruitment of the DCAF16 E3 ubiquitin ligase. Demonstrating a favorable safety profile, this compound effectively degrades AR in LNCaP prostate cancer cells without inducing significant cytotoxicity.

BRD4 degrader-2 (Compound JP-2-197) is a covalent monovalent molecular glue that orchestrates targeted BRD4 degradation through ternary complex formation with the E3 ligase RNF126. This compound selectively engages both BRD4 isoforms (long and short) for proteasomal elimination, demonstrating pan-isoform degradation capability in cellular systems.

3-Indoleacetic acid (Standard) serves as an analytically validated reference material for the phytohormone indole-3-acetic acid (IAA). Designed for precision research applications, this auxin-class plant growth regulator modulates fundamental developmental processes including cellular expansion, tissue differentiation, and organ morphogenesis, driving vegetative growth in plant systems.

ChREBPα/14-3-3 regulator-1 (Compound 43) is a selective molecular glue that stabilizes the ChREBP/14-3-3 protein complex with an EC50 of 3.8 μM. By enhancing this interaction, the compound demonstrates cytoprotective effects against glucolipotoxicity in pancreatic β cells while preserving cellular function. These properties position it as a promising investigational tool for type 2 diabetes research.

BRD9 Degrader-2 (Compound B11) is a highly potent and efficient molecular degrader of BRD9, achieving sub-nanomolar degradation activity (DC50 ≤1.25 nM) with maximal degradation exceeding 75%. This compound represents a promising chemical tool for investigating BRD9-dependent oncogenic pathways in cancer research.

AR Degrader-2 (Compound 2) is a molecular glue compound that induces targeted degradation of the androgen receptor (AR), demonstrating potent activity with a DC50 ranging from 0.3 to 0.5 μM in VCaP prostate cancer cells.

rac-Lenalidomide-13C5 is a carbon-13 labeled racemic variant of lenalidomide, designed for tracer studies in pharmacokinetic and metabolic research.

Lenalidomide-13C5,15N is an isotopically labeled analog of lenalidomide (HY-A0003; CC-5013), a thalidomide-derived molecular glue compound. This orally bioavailable immunomodulator functions through selective cereblon (CRBN) E3 ubiquitin ligase engagement, mediating targeted ubiquitination and proteasomal degradation of lymphoid transcription factors IKZF1 and IKZF3 via the CRBN-CRL4 complex. The compound demonstrates dual therapeutic activity by both suppressing proliferation of mature B-cell malignancies (including multiple myeloma) and enhancing T-cell immunostimulation through IL-2 induction.

3-Indoleacetic acid-d4 (Indole-3-acetic acid-d4; 3-IAA-d4) is a deuterium-stabilized isotopologue of the endogenous auxin phytohormone 3-indoleacetic acid (HY-18569). As the predominant natural auxin, 3-IAA regulates fundamental plant growth processes, including cellular elongation and proliferation, when supplemented in plant tissue culture systems.

Antitumor agent-100 (compound A6) hydrochloride is an orally bioavailable molecular glue that selectively targets the PDE3A-SLFN12 complex (IC50 = 0.3 μM). By binding to the PDE3A catalytic pocket, it stabilizes SLFN12 interaction, subsequently inhibiting protein translation and triggering apoptotic cell death. This dual mechanism underlies its potent antitumor activity.

CCT373567 demonstrates potent and selective BCL6 inhibition, exhibiting an IC50 of 2.9 nM in biochemical TR-FRET assays and 25.9 nM in cellular NanoBRET assays. This cell-permeable compound maintains robust activity in physiological settings, highlighting its potential as a targeted therapeutic agent.

GSPT1 degrader-4 (compound 3) functions as a potent molecular glue targeting GSPT1, demonstrating a degradation concentration (DC50) of 25.4 nM. The compound exhibits strong anti-proliferative activity in CAL51 cells with an IC50 value of 39 nM.

FIZ1 degrader 1 (compound 1) represents a novel IMiD-derived molecular glue compound engineered for targeted FIZ1 protein degradation.

BRD9 Degrader-4 (BRD9c) is a highly potent bifunctional molecular glue compound that induces targeted degradation of BRD9, demonstrating exceptional activity with a DC50 value of 25 nM or lower. This degradative capability translates to significant anti-tumor efficacy, highlighting its potential as a therapeutic agent.

Avadomide hydrochloride (CC-122 hydrochloride), the salt form of Avadomide (HY-100507), is an orally bioavailable cereblon-targeting agent that exerts potent antitumor and immunomodulatory effects. By modulating cereblon E3 ubiquitin ligase activity, this compound inhibits the NF-κB signaling pathway and induces G1 phase cell cycle arrest, ultimately triggering apoptosis in PDAC cancer cells.

IPS-06061 is an orally bioavailable molecular glue that mediates targeted degradation of KRAS G12D through formation of a CRBN-KRASG12D-IPS06061 ternary complex, demonstrating potent activity with a DC50 below 500 nM.

Lenalidomide hydrochloride (CC-5013 hydrochloride), a thalidomide-derived molecular glue, functions as an orally bioavailable immunomodulatory agent. By binding to the ubiquitin E3 ligase cereblon (CRBN), it recruits the CRBN-CRL4 complex to induce selective ubiquitination and degradation of lymphoid transcription factors IKZF1 and IKZF3. This mechanism underlies its potent activity against mature B-cell malignancies, including multiple myeloma, while also stimulating IL-2 secretion from T cells.

The R-enantiomer of thalidomide, (R)-(+)-thalidomide, exhibits sedative effects distinct from its racemic counterpart.

Cyclosporin A (Cyclosporine A) is a potent immunosuppressive agent commonly administered after allogeneic organ transplants to suppress immune system activity and prevent rejection.

CDO1 Degrader-1 (Compound 8) is a molecular glue that targets cysteine dioxygenase (CDO1) for degradation.

HuR Degrader 2 (Compound 3) is a molecular glue that targets the RNA-binding protein HuR, degrading ~30% of HuR at 0.1 μM. It inhibits the proliferation of Colo-205 cancer cells with an IC50 ≤ 200 nM and exhibits high cereblon binding affinity, as evidenced by an HTRF ratio < 0.02.

Asukamycin, a macrolide polyketide derived from Streptomyces nodosus subsp. asukaensis, exhibits dual antimicrobial and antitumor activities. This natural product demonstrates broad-spectrum antibiotic properties while selectively inhibiting tumor cell proliferation through caspase-8/3-mediated apoptosis induction.

Tri-GalNAc(OAc)3 TFA is a tri-GalNAc ligand that can be used for the synthesis of GalNAc-LYTAC. GalNAc-LYTAC engages the asialoglycoprotein receptor for targeted protein degradation. tri-GalNAc: triantenerrary N-acetylgalactosamine; LYTAC: lysosome-targeting chimera.